Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
McKesson
Mallinckrodt
Colorcon
Boehringer Ingelheim

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN ASPART

See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Insulin Aspart

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01487811 Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers Completed Novo Nordisk A/S Phase 1 2005-05-01 This trial is conducted in the United states of America (USA). The aim of this trial is to compare two formulations of biphasic insulin aspart 30 in healthy volunteers.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Insulin Aspart

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00046150 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. Completed Sanofi Phase 3 2002-05-01 The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs.
NCT00065130 Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes Completed Novo Nordisk A/S Phase 3 2000-04-01 This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
NCT00071448 Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population Completed Novo Nordisk A/S Phase 3 2002-06-01 This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Aspart

Condition Name

Condition Name for Insulin Aspart
Intervention Trials
Diabetes 252
Diabetes Mellitus, Type 2 157
Diabetes Mellitus, Type 1 121
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Insulin Aspart
Intervention Trials
Diabetes Mellitus 316
Diabetes Mellitus, Type 2 191
Diabetes Mellitus, Type 1 158
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Insulin Aspart

Trials by Country

Trials by Country for Insulin Aspart
Location Trials
United States 923
Germany 80
China 60
India 54
Canada 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Insulin Aspart
Location Trials
California 56
Texas 54
Florida 46
Georgia 40
New York 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Insulin Aspart

Clinical Trial Phase

Clinical Trial Phase for Insulin Aspart
Clinical Trial Phase Trials
Phase 4 114
Phase 3 96
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Insulin Aspart
Clinical Trial Phase Trials
Completed 293
Recruiting 34
Not yet recruiting 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Insulin Aspart

Sponsor Name

Sponsor Name for Insulin Aspart
Sponsor Trials
Novo Nordisk A/S 271
Sanofi 16
Eli Lilly and Company 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Insulin Aspart
Sponsor Trials
Industry 333
Other 141
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
Express Scripts
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.